Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$14.62 USD
+0.84 (6.10%)
Updated May 31, 2024 04:00 PM ET
After-Market: $14.59 -0.03 (-0.21%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Stoke Therapeutics, Inc. [STOK]
Reports for Purchase
Showing records 21 - 40 ( 91 total )
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts on ADMIRAL and MONARCH Data Readout; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Stoke?s Opportunity in the Current Regulatory Environment; Reit Buy and $35 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Moving Towards MONARCH, ADMIRAL -- 4Q22 Key Takeaways
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Higher Dosing and Younger Patients Might be Key for STK001; Reit. Buy and PT Reduced to $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
STK-001 MONARCH/ADMIRAL Data Arrives - Thoughts and Context
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expectations From STK-001?s Upcoming Interim Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- The Wedbush Monthly Check-Up: October 2022
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - Ever Evolving Genetic Medicines
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
With The Wind At Their Backs, Looking Ahead to STK-001 Data
Provider: Wedbush Securities Inc.
Analyst: CHOPRA R
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts on the Upcoming STK-001''s Interim Data Readout; Reiterate Buy and $70 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Will MONARCH Reign Over Dravet? Looks Like We''ll Find Out In 4Q22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Not Your Father''s ASM: Takeaways From Management Call
Provider: Wedbush Securities Inc.
Analyst: CHICO L